ipamorelin retatrutide (RUO) | Selective GHS-R1a Agonist Shop Peptides - Planet Peptide
Description
The 9mg dose led to 26.4% weight loss
Degradation was slower than for hGLP-1 but clearly measurable, with less than 50% uncleaved pGLP-1 and eGLP-1 remaining after 11 hours of incubation (Table 1)
doi: 10.3389/fgene.2020.00903
The GIP receptor activation appears to reduce nausea compared to pure GLP-1 agonists, which is why retatrutide shows a 28% nausea rate versus 44% for semaglutide despite being more potent
As a peptide-based injectable targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide shares the same temperature sensitivity as approved agents such as semaglutide and tirzepatide
